Robert LeBoyer
Stock Analyst at Noble Capital Markets
(0)
# 3120
Out of 5,243 analysts
18
Total ratings
35.71%
Success rate
5.27%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Geovax Labs | Maintains: Outperform | 6 10 | 2.23 | 348.43% | 2 | Aug 19, 2024 | |
Unicycive Therapeuti... | Initiates Coverage On: Outperform | 6 | 0.65 | 823.08% | 1 | Feb 14, 2024 | |
Cadrenal Therapeutic... | Initiates Coverage On: Outperform | 60 | 16.35 | 266.97% | 1 | Dec 18, 2023 | |
Eledon Pharma | Initiates Coverage On: Outperform | 10 | 4 | 150% | 1 | Sep 27, 2023 | |
MAIA Biotechnology | Initiates Coverage On: Outperform | 14 | 2.16 | 548.15% | 1 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Sep 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 3840 | 0.23 | 1669465.22% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 150 | n/a | n/a | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 8 | 0.57 | 1303.51% | 2 | Aug 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 120 | 1.21 | 9817.36% | 1 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 11.26 | 6.57% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16500 | 0.11 | 14999900% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 15 | 6.65 | 125.56% | 2 | Mar 8, 2018 |